Format

Send to

Choose Destination
Int J Infect Dis. 2015 Mar;32:156-60. doi: 10.1016/j.ijid.2014.12.024.

Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium.

Author information

1
World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Via Roncaccio 16, 21049, Tradate, Italy. Electronic address: lia.dambrosio@fsm.it.
2
Section of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Via Massarenti 11, 40138, Bologna, Italy. Electronic address: mtadolini@hotmail.com.
3
World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Via Roncaccio 16, 21049, Tradate, Italy. Electronic address: rosella.centis@fsm.it.
4
Pneumologia, Centro de Diagnóstico Pneumológico, Vila Nova de Gaia, Rua Conceição Fernandes 4430 Portugal. Electronic address: raquelafduarte@gmail.com.
5
Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences - University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, via Padre Manzella, 4, 07100, Sassari, Italy. Electronic address: gsotgiu@uniss.it.
6
Health Science Department, University of Milan Bicocca, Respiratory Unit, AO San Gerardo, Via Pergolesi 33, 20052, Monza, Italy. Electronic address: stefano.aliberti@unimib.it.
7
World Health Organization, Regional Office for Europe, UN City Marmorvej 51 DK-2100 Copenhagen Ø, Denmark. Electronic address: MDD@euro.who.int.
8
World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Via Roncaccio 16, 21049, Tradate, Italy. Electronic address: giovannibattista.migliori@fsm.it.

Abstract

Multi-drug and extensively drug-resistant tuberculosis (MDR/XDR-TB) are considered a serious threat for TB control and elimination. The outcome of these patients is still largely unsatisfactory as of today, with treatment success rates being consistently below 50% at global level. The World Health Organization (WHO) recommends that management of MDR-TB cases is supported by a specialized team, including complementary medical professionals able to cover several perspectives (clinical, both for adults and children; surgical; radiological; public health; psychological; nursing, among others). Implementation of such a body (known as Consilium in most of the former Soviet Union countries) is often a pre-requisite to apply for international TB control funding and concessionally priced medicines to treat M/XDR-TB cases. The primary objective of the ERS/WHO TB Consilium is to provide clinical consultation for drug-resistant TB and other difficult-to-treat TB cases, including co-infection with HIV and paediatric cases. Through technical guidance to clinicians managing complex TB cases, the main contribution and outcome of the initiative will be a public health response aimed at achieving correct treatment of affected patients and preventing further development of drug resistance. The Consilum's secondary objective is to ensure monitoring and evaluation of clinical practices on the ground (diagnosis, treatment and prevention).

KEYWORDS:

ERS/WHO Consilium; MDR-TB; XDR-TB; clinical management; drug resistance; prevention

PMID:
25809773
DOI:
10.1016/j.ijid.2014.12.024
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center